• 30 Hits
  • Search Condition : Filter (MeSH = Ovarian Neoplasms / drug therapy*)
Species Resource Title
Human and Animal Cells KGN(RCB1154) Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
Human and Animal Cells JHOM-1(RCB1676) , JHOM-2B(RCB1682) Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
Human and Animal Cells JHOC-5(RCB1520) Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Human and Animal Cells JHOS-2(RCB1521) , JHOC-5(RCB1520) CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
Human and Animal Cells KGN(RCB1154) Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
Human and Animal Cells HHUA(RCB0658) Growth-inhibitory signals by activin A do not affect anticancer drug-sensitivity and acquired multi-drug-resistance in human ovarian endometrioid adenocarcinoma OVK-18 cells.
Human and Animal Cells HHUA(RCB0658) Novel target genes responsive to the anti-growth activity of triptolide in endometrial and ovarian cancer cells.
Human and Animal Cells HHUA(RCB0658) PK11195 enhances chemosensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer cells.
Human and Animal Cells JHOS-2(RCB1521) , JHOS-4(RCB1678) Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
Human and Animal Cells JHOC-7(RCB1688) , JHOC-9(RCB2226) Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys.
Human and Animal Cells OVK18(RCB1903) , JHOC-5(RCB1520) , JHOC-7(RCB1688) , JHOC-8(RCB1723) , JHOC-9(RCB2226) , JHOS-2(RCB1521) , JHOS-4(RCB1678) Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models.
Human and Animal Cells OV2944-HM-1(RCB1483) Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
Human and Animal Cells JHOC-5(RCB1520) , JHOC-7(RCB1688) , JHOC-9(RCB2226) Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
Human and Animal Cells JHOC-7(RCB1688) Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Human and Animal Cells OVK18(RCB1903) Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.
Human and Animal Cells JHOC-9(RCB2226) Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Human and Animal Cells JHOC-5(RCB1520) Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Human and Animal Cells JHOS-2(RCB1521) , JHOS-3(RCB1546) , JHOS-4(RCB1678) Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Human and Animal Cells JHUEM-2(RCB1551) Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Human and Animal Cells JHOC-5(RCB1520) ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.